{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:41:57Z","timestamp":1794069717394,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Basic Science Research Program through the National Research Foundation of Korea","award":["2022R1C1C1005736"],"award-info":[{"award-number":["2022R1C1C1005736"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with idiopathic pulmonary fibrosis (IPF) often experience weight loss during the follow-up period. However, the prevalence and clinical impact of weight loss in these patients still need to be elucidated. This retrospective single-center study reviewed 134 consecutive patients diagnosed with IPF. Weight loss of 5% or more over 1\u00a0year was defined as significant weight loss. Clinical data of patients were compared according to the significant weight loss. We analyzed whether the clinical impact of significant weight loss differed regarding the pirfenidone dose. The median follow-up period was 22.1\u00a0months. The mean age of patients was 67.3\u00a0years, and 92.5% were men. Of the 134 patients, 42 (31.3%) showed significant weight loss. Multivariate cox regression analysis revealed that significant weight loss was independently associated with mortality (hazard ratio [HR]; 2.670; 95% confidence interval [CI] 1.099\u20136.484;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.030) after adjusting for lung function and other significant risk factors (6-min walk test distance: HR, 0.993; 95% CI 0.987\u20130.998;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005). The median survival of patients with significant weight loss (n\u2009=\u200922) was relevantly shorter than that of those without significant weight loss (n\u2009=\u200943) in the reduced dose pirfenidone group (28.2\u2009\u00b1\u20093.3 vs. 43.3\u2009\u00b1\u20093.2\u00a0months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.013). Compared with patients without significant weight loss (n\u2009=\u200938), patients with significant weight loss (n\u2009=\u200915) also showed a marginally-significant shorter survival in the full-dose pirfenidone group (28.9\u2009\u00b1\u20093.1 vs. 39.8\u2009\u00b1\u20092.6\u00a0months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.085). Significant weight loss is a prognostic factor in patients with IPF regardless of pirfenidone dose. Vigilant monitoring might be necessary to detect weight loss during the clinical course in these patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-32843-7","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T06:02:40Z","timestamp":1680933760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical impact of weight loss on mortality in patients with idiopathic pulmonary fibrosis: a retrospective cohort study"],"prefix":"10.1038","volume":"13","author":[{"given":"Ju Kwang","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiwook","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Sin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"key":"32843_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer, D. J. & Martinez, F. J. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 378, 1811\u20131823 (2018).","journal-title":"N. Engl. J. Med."},{"key":"32843_CR2","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","volume":"378","author":"TE King Jr","year":"2011","unstructured":"King, T. E. Jr., Pardo, A. & Selman, M. Idiopathic pulmonary fibrosis. Lancet 378, 1949\u20131961 (2011).","journal-title":"Lancet"},{"key":"32843_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000490355","volume":"96","author":"Y Nakatsuka","year":"2018","unstructured":"Nakatsuka, Y. et al. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration 96, 338\u2013347 (2018).","journal-title":"Respiration"},{"key":"32843_CR4","doi-asserted-by":"publisher","first-page":"1801289","DOI":"10.1183\/13993003.01289-2018","volume":"52","author":"J Pugashetti","year":"2018","unstructured":"Pugashetti, J. et al. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur. Respir. J. 52, 1801289 (2018).","journal-title":"Eur. Respir. J."},{"key":"32843_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000446607","volume":"91","author":"T Bahmer","year":"2016","unstructured":"Bahmer, T. et al. Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis. Respiration 91, 497\u2013502 (2016).","journal-title":"Respiration"},{"key":"32843_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.freeradbiomed.2010.04.036","volume":"49","author":"CR Kliment","year":"2010","unstructured":"Kliment, C. R. & Oury, T. D. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 49, 707\u2013717 (2010).","journal-title":"Free Radic. Biol. Med."},{"key":"32843_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00408-019-00260-1","volume":"197","author":"VLJ Proesmans","year":"2019","unstructured":"Proesmans, V. L. J. et al. Self-reported gastrointestinal side effects of antifibrotic drugs in Dutch idiopathic pulmonary fibrosis patients. Lung 197, 551\u2013558 (2019).","journal-title":"Lung"},{"key":"32843_CR8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092 (2014).","journal-title":"N. Engl. J. Med."},{"key":"32843_CR9","doi-asserted-by":"publisher","first-page":"21218","DOI":"10.1038\/s41598-020-77837-x","volume":"10","author":"MJ Song","year":"2020","unstructured":"Song, M. J. et al. Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: Real world experience from a tertiary university hospital. Sci. Rep. 10, 21218 (2020).","journal-title":"Sci. Rep."},{"key":"32843_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12931-020-01528-4","volume":"21","author":"S Jouneau","year":"2020","unstructured":"Jouneau, S. et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir. Res. 21, 312 (2020).","journal-title":"Respir. Res."},{"key":"32843_CR11","doi-asserted-by":"publisher","first-page":"e0221905","DOI":"10.1371\/journal.pone.0221905","volume":"14","author":"T Kulkarni","year":"2019","unstructured":"Kulkarni, T. et al. Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS One 14, e0221905 (2019).","journal-title":"PLoS One"},{"key":"32843_CR12","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/crj.12700","volume":"12","author":"M Doubkov\u00e1","year":"2018","unstructured":"Doubkov\u00e1, M. et al. EMPIRE registry, czech part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin. Respir. J. 12, 1526\u20131535 (2018).","journal-title":"Clin. Respir. J."},{"key":"32843_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/resp.12941","volume":"22","author":"O Nishiyama","year":"2017","unstructured":"Nishiyama, O. et al. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology 22, 480\u2013485 (2017).","journal-title":"Respirology"},{"key":"32843_CR14","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 198, e44\u2013e68 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32843_CR15","first-page":"510","volume":"8","author":"NR Sahyoun","year":"2004","unstructured":"Sahyoun, N. R., Serdula, M. K., Galuska, D. A., Zhang, X. L. & Pamuk, E. R. The epidemiology of recent involuntary weight loss in the United States population. J. Nutr. Health Aging 8, 510\u2013517 (2004).","journal-title":"J. Nutr. Health Aging"},{"key":"32843_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.mcna.2014.01.012","volume":"98","author":"CJ Wong","year":"2014","unstructured":"Wong, C. J. Involuntary weight loss. Med. Clin. N. Am. 98, 625\u2013643 (2014).","journal-title":"Med. Clin. N. Am."},{"key":"32843_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1183\/09031936.05.00035005","volume":"26","author":"J Wanger","year":"2005","unstructured":"Wanger, J. et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 26, 511\u2013522 (2005).","journal-title":"Eur. Respir. J."},{"key":"32843_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1183\/09031936.05.00034905","volume":"26","author":"N Macintyre","year":"2005","unstructured":"Macintyre, N. et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 26, 720\u2013735 (2005).","journal-title":"Eur. Respir. J."},{"key":"32843_CR19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1183\/09031936.00150314","volume":"44","author":"AE Holland","year":"2014","unstructured":"Holland, A. E. et al. An official European Respiratory Society\/American Thoracic Society technical standard: Field walking tests in chronic respiratory disease. Eur. Respir. J. 44, 1428\u20131446 (2014).","journal-title":"Eur. Respir. J."},{"key":"32843_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi, H. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 35, 821\u2013829 (2010).","journal-title":"Eur. Respir. J."},{"key":"32843_CR21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley, B. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 156, 684\u2013691 (2012).","journal-title":"Ann. Intern. Med."},{"key":"32843_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12890-017-0444-0","volume":"17","author":"T Bahmer","year":"2017","unstructured":"Bahmer, T. et al. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm. Med. 17, 104 (2017).","journal-title":"BMC Pulm. Med."},{"key":"32843_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.mcp.0000208449.73101.ac","volume":"12","author":"VP Balasubramanian","year":"2006","unstructured":"Balasubramanian, V. P. & Varkey, B. Chronic obstructive pulmonary disease: Effects beyond the lungs. Curr. Opin. Pulm. Med. 12, 106\u2013112 (2006).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"32843_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12931-019-1073-3","volume":"20","author":"MN McDonald","year":"2019","unstructured":"McDonald, M. N. et al. It\u2019s more than low BMI: Prevalence of cachexia and associated mortality in COPD. Respir. Res. 20, 100 (2019).","journal-title":"Respir. Res."},{"key":"32843_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.rmed.2015.04.009","volume":"109","author":"AA D\u00edaz","year":"2015","unstructured":"D\u00edaz, A. A. et al. Emphysema and DLCO predict a clinically important difference for 6MWD decline in COPD. Respir. Med. 109, 882\u2013889 (2015).","journal-title":"Respir. Med."},{"key":"32843_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000327918","volume":"82","author":"G Pitsiou","year":"2011","unstructured":"Pitsiou, G., Papakosta, D. & Bouros, D. Pulmonary hypertension in idiopathic pulmonary fibrosis: A review. Respiration 82, 294\u2013304 (2011).","journal-title":"Respiration"},{"key":"32843_CR27","unstructured":"World Health Organization The Asia-Pacific perspective: redefining obesity and its treatment (2000)."},{"key":"32843_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/nu12041131","volume":"12","author":"P Faverio","year":"2020","unstructured":"Faverio, P. et al. Nutrition in patients with idiopathic pulmonary fibrosis: Critical issues analysis and future research directions. Nutrients 12, 1131 (2020).","journal-title":"Nutrients"},{"key":"32843_CR29","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.clnu.2022.05.001","volume":"41","author":"S Jouneau","year":"2022","unstructured":"Jouneau, S. et al. Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clin. Nutr. 41, 1335\u20131342 (2022).","journal-title":"Clin. Nutr."},{"key":"32843_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5603\/ARM.a2020.0193","volume":"89","author":"AJ Bia\u0142as","year":"2021","unstructured":"Bia\u0142as, A. J. et al. The prognostic value of fixed time and self-paced walking tests in patients diagnosed with idiopathic pulmonary fibrosis. Adv. Respir. Med. 89, 49\u201354 (2021).","journal-title":"Adv. Respir. Med."},{"key":"32843_CR31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1378\/chest.08-0754","volume":"135","author":"DA Zisman","year":"2009","unstructured":"Zisman, D. A. et al. Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia. Chest 135, 929\u2013935 (2009).","journal-title":"Chest"},{"key":"32843_CR32","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1183\/09031936.00146314","volume":"45","author":"B Ley","year":"2015","unstructured":"Ley, B. et al. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur. Respir. J. 45, 1374\u20131381 (2015).","journal-title":"Eur. Respir. J."},{"key":"32843_CR33","doi-asserted-by":"publisher","first-page":"A120","DOI":"10.1136\/thoraxjnl-2012-202678.417","volume":"67","author":"M Wilkie","year":"2012","unstructured":"Wilkie, M., Chalmers, J., Smith, R. & Schembri, S. P134 comparison of two prognostic tools for identifying high risk patients with idiopathic pulmonary fibrosis. Thorax 67, A120\u2013A120 (2012).","journal-title":"Thorax"},{"key":"32843_CR34","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1038\/s41598-018-23073-3","volume":"8","author":"SH Lee","year":"2018","unstructured":"Lee, S. H. et al. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: A nationwide cohort study. Sci. Rep. 8, 4784 (2018).","journal-title":"Sci. Rep."},{"key":"32843_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.resinv.2016.02.009","volume":"54","author":"S Kondoh","year":"2016","unstructured":"Kondoh, S. et al. Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis. Respir. Investig. 54, 327\u2013333 (2016).","journal-title":"Respir. Investig."},{"key":"32843_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000518855","volume":"101","author":"S Jouneau","year":"2022","unstructured":"Jouneau, S. et al. Post hoc analysis of clinical outcomes in placebo- and pirfenidone-treated patients with IPF stratified by BMI and weight loss. Respiration 101, 142\u2013154 (2022).","journal-title":"Respiration"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32843-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T06:10:09Z","timestamp":1680934209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32843-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32843"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32843-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2214669\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5774"}}